Highest-materiality recent filing
Danaher completes $180/share acquisition of Masimo; Masimo becomes wholly owned subsidiary
Danaher completed acquisition of Masimo at $180.00 per share in cash on June 10, 2026.
Masimo shareholders approve Danaher acquisition at $180/share
Merger adoption proposal passed: 36,981,681 for (99.95% of votes cast), 17,061 against.
Masimo provides supplemental proxy disclosures amid three stockholder lawsuits over Danaher merger
Three stockholder lawsuits filed in NY and CA allege Masimo's proxy statement is incomplete; company denies merit.
Danaher to acquire Masimo for $180/share cash; total value $9.9B
Masimo shareholders to receive $180.00 per share in cash for each share held.
Masimo preliminary Q4 rev $411M (+12% YoY); FY25 rev $1,523M (+9%), non-GAAP EPS >$5.55
Q4 revenue ~$411M (~12% reported growth; 11% constant currency).
Masimo targets 7-10% revenue CAGR through 2028; reaffirms FY2025 guidance
Long-range targets: 7%-10% revenue CAGR through 2028, ~30% operating margin by 2028.
Masimo refinances debt with $250M term loan and $750M revolver maturing 2030
Paid off prior credit facility (April 2022, Citibank admin) on Dec 1, 2025, and terminated commitments.
Masimo Q3 revenue $371.5M (+8.2%), non-GAAP EPS $1.32 (+38%); updates FY2025 guidance
GAAP revenue $371.5M (+8.2% YoY); GAAP diluted EPS $0.99; non-GAAP EPS $1.32 (+38% YoY).
Masimo completes sale of consumer audio business to Harman for ~$328M cash; repays $270M Term Loan
Sold Sound United (consumer audio) to Harman on Sept 23, 2025 for net cash ~$328M.
Masimo completes sale of consumer audio unit to HARMAN for $350M; to prioritize share repurchases
Closed sale of Sound United to Harman (Samsung subsidiary) for $350M cash; received ~$328M at close subject to adjustments.
Director William Jellison resigns from Masimo board effective August 18, 2025
William Jellison resigned from the Board of Directors effective August 18, 2025.
Masimo Q2 revenue $371M (+8% YoY); Non-GAAP EPS $1.33 (+46%); tariff impact halved
GAAP revenue $371M (+8% YoY); GAAP diluted EPS $0.82; Non-GAAP diluted EPS $1.33 (+46%).
Masimo adds CMO, President Japan/APAC, CHRO; COO Muhsin resigns effective July 1
Tim Benner joins as Chief Marketing and Strategy Officer, started June 9, 2025.
Manufacturing running at near full capacity; order-taking, distribution and shipping systems fully operational.
Masimo sells consumer audio business (Sound United) to Harman for $350M cash
Sale of Viper Holdings (Sound United) to Harman International for base price of $350M cash, subject to working capital adjustments.
Masimo Q1 non-GAAP EPS $1.36 (+56% YoY); core revenue $372M (+10%); FY guidance cut on tariffs
GAAP revenue $372M, up 10% YoY; non-GAAP EPS $1.36, up 56% from prior year.
Discovered unauthorized activity on on-premise network on April 27, 2025; activated incident response and containment protocols.
Masimo to sell Sound United consumer audio business to HARMAN for $350M cash
Sale to HARMAN, a Samsung subsidiary, for $350M in cash, subject to adjustments.
Masimo shareholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting
Elected William Jellison, Wendy Lane, Timothy Scannell, Darlene Solomon, Catherine Szyman as directors for 2026 term.
Masimo Q4 revenue $601M (+9%); Non-GAAP EPS $1.80 (+44%); FY2025 guide sees healthcare growth 8-11%
Q4 revenue $601M (+9% YoY); Healthcare $368M (+8%), Non-healthcare $232M (+11%).
Masimo amends bylaws; reduces special meeting threshold to 20%, sets April 29 annual meeting
Board approved Restated Bylaws; stockholders with 20% voting power can call special meetings.
Masimo terminates EVP, General Counsel Tom McClenahan; no replacement named
Tom McClenahan terminated as EVP, General Counsel and Corporate Secretary, effective Feb 6, 2025.
Director Robert Chapek resigns from Masimo board effective at 2025 annual meeting
Robert Chapek voluntarily resigned as director, effective at the 2025 annual meeting (date TBD).
Masimo appoints Catherine Szyman as CEO, effective Feb 12; Michelle Brennan becomes Chairman
Katie Szyman appointed CEO effective Feb 12; previously led Edwards Critical Care (acquired by BD); 35+ yrs experience.
Masimo reports preliminary Q4 2024 revenue ~$601M, healthcare up 9%; issues FY 2025 guidance
Q4 2024 consolidated revenue ~$601M (+9% YoY); healthcare revenue ~$368M (+8% reported, +9% constant currency).
Masimo formalizes interim CEO Michelle Brennan's employment agreement
Base salary of $1,042,000 per year; eligible for discretionary bonus with target $621,250.
Masimo terminates EVP Business Development Tao Levy as part of healthcare refocus
Terminated Tao Levy, EVP Business Development, effective November 13, 2024.
Masimo Q3 healthcare revenue up 11.7% CC; raises FY non-GAAP EPS guidance to $3.95-$4.10
Healthcare revenue $343.3M (+11.7% CC); total revenue $504.6M; 60,500 board/instrument shipments.
Masimo terminates CEO Joe Kiani; reaffirms non-GAAP guidance for Q3 and FY 2024
Board terminated CEO Joe Kiani effective Oct 24, 2024 following review by outside counsel.
Masimo appoints Timothy Scannell and Wendy Lane to board, expands to eight directors
Scannell, former Stryker President & COO, brings 30+ years med-tech experience; Lane has 32 years of board service across 16 companies.
Joe Kiani resigned as CEO on Sept 19, 2024, and filed a California lawsuit claiming 'Good Reason' termination.
Exclusivity with JV partner expired; discussions continue non-exclusively; Masimo may engage other acquirors.
Masimo Q2 revenue $496.3M, GAAP EPS $0.29, non-GAAP $0.86; raises FY2024 guidance
Healthcare revenue $343.9M, non-healthcare $152.4M; GAAP operating income $28.3M, non-GAAP $72.9M.
Masimo postpones annual meeting to Sept 19, sues Politan over proxy misstatements
Annual meeting postponed to Sept 19, 2024; new record date Aug 12, 2024.
Masimo preliminary Q2 revenue $496M (+9%); healthcare up 22%
Consolidated revenue ~$496M, +9% reported, +10% constant currency YoY.
Masimo Receives Non-Binding Offer of $850M-$950M for Consumer Business from Potential JV Partner
Masimo entered non-binding term sheet with Potential JV Partner on May 7, 2024, for sale of majority stake in consumer businesses.
Masimo COO conditional resignation letter if CEO Kiani removed due to activist Politan
Bilal Muhsin (COO) sent a conditional resignation letter on June 26, 2024, stating he will resign if Joe Kiani is removed as Chairman and CEO.
Masimo files investor presentation outlining potential separation of consumer business
Filed investor presentation dated June 2024 with estimates and projections for a potential separation of Masimo's consumer business.
Masimo corrects recall scope: 27,600 Rad-G units affected; DOJ investigation ongoing
Recall affects ~7,350 U.S. and ~20,250 non-U.S. Rad-G units due to unintended power state change.
Rolf Classon notified Board on May 3, 2024 of resignation effective May 10, 2024 for personal health reasons.
Masimo Q1 rev $492.8M (healthcare $339.6M), GAAP EPS $0.35, Non-GAAP $0.77; lifts FY2024 outlook
Consolidated Q1 revenue $492.8M; healthcare $339.6M, non-healthcare $153.2M.
Masimo board authorizes evaluation of consumer business separation; retains healthcare
Board authorized management to evaluate separation of consumer business (audio + health products: Stork, Freedom).
Masimo Q4 revenue $548.9M, GAAP EPS $0.63; full-year $2,048.1M; FY2024 guidance $2,045-2,165M
Q4 consolidated revenue $548.9M (healthcare $339.9M, non-healthcare $209.0M).
Director Adam Mikkelson notified Board of resignation effective Feb 29, 2024, for personal reasons, not due to any disagreement with Masimo.
Masimo appoints former Disney CEO Bob Chapek to Board of Directors
Robert A. Chapek, former CEO of The Walt Disney Company, appointed Class I director effective January 15, 2024.
Masimo reports preliminary Q4 2023 rev $541-551M; FY2024 rev guidance $2.045-2.165B
Preliminary Q4 2023 consolidated revenue $541M-$551M; healthcare segment $336M-$341M.
Delaware court awards Politan $17.8M in fees against Masimo
Delaware Court of Chancery granted Politan's motion for $17.8 million in attorneys' fees and expenses.
Masimo Q3 rev $478.9M, GAAP EPS $0.20; Q4 guide rev $526-$576M
Q3 consolidated rev $478.9M: healthcare $307.8M, non-healthcare $171.1M.
Masimo appoints Rolf Classon to board of directors
Rolf A. Classon appointed as a Class II director effective November 3, 2023.
ITC found Apple violated Section 337; claims 22 & 28 of '502 patent and claims 12, 24, 30 of '648 patent infringed.
Micah Young, Chief Financial Officer, has recently assumed leadership of the corporate development function in addition to his responsibilities overseeing finance, IT and investor relations.
On June 6, 2025, Bilal Muhsin, Chief Operating Officer, informed the Company he was resigning to pursue other opportunities, effective July 1, 2025.
Huimin Wang has joined as President, Japan & Asia Pacific and started on May 13, 2025.
Tim Benner has joined as Chief Marketing and Strategy Officer and started on June 9, 2025.
Lisa Hellmann has joined as Chief Human Resources Officer and started on April 21, 2025.
On February 6, 2025, Masimo Corporation (the “ Company ”) terminated the employment of Tom McClenahan, the Company’s Executive Vice President, General Counsel and Corporate Secretary, effective as of February 6, 2025 .
On January 30, 2025, Robert Chapek notified the Board of Directors (the “Board”) of Masimo Corporation (“Masimo”) of his irrevocable resignation from the Board and all committees thereof, effective as of the date of the 2025 annual meeting of Masimo, which date the Board has not determined at this time.
has been appointed to the role of Chairman of the Board
Michelle Brennan will cease to serve as Interim Chief Executive Officer of the Company
appointed Catherine Szyman, 58, as Chief Executive Officer of the Company, effective as of February 12, 2025
Quentin Koffey will serve in the role of Vice-Chairman of the Board
On November 13, 2024, in connection with its strategic shift to refocus on its core healthcare business, Masimo Corporation (the “ Company ”) terminated the employment of Tao Levy, the Company’s Executive Vice President, Business Development.
Max materiality 1.00 · Median 0.70 · Most common event leadership